Amgen Inc. (NASDAQ:AMGN) Shares Sold by LVM Capital Management Ltd. MI

LVM Capital Management Ltd. MI reduced its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 32.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 40,671 shares of the medical research company's stock after selling 19,490 shares during the quarter. Amgen accounts for 1.1% of LVM Capital Management Ltd. MI's investment portfolio, making the stock its 27th biggest holding. LVM Capital Management Ltd. MI's holdings in Amgen were worth $10,600,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of AMGN. Strategic Financial Concepts LLC purchased a new stake in shares of Amgen in the second quarter valued at approximately $26,000. MGO One Seven LLC grew its stake in shares of Amgen by 17.5% during the 2nd quarter. MGO One Seven LLC now owns 7,113 shares of the medical research company's stock worth $2,223,000 after purchasing an additional 1,061 shares during the period. Angeles Wealth Management LLC increased its holdings in shares of Amgen by 12.3% in the 2nd quarter. Angeles Wealth Management LLC now owns 828 shares of the medical research company's stock valued at $259,000 after purchasing an additional 91 shares in the last quarter. LPL Financial LLC lifted its stake in shares of Amgen by 9.9% in the second quarter. LPL Financial LLC now owns 746,946 shares of the medical research company's stock valued at $233,383,000 after purchasing an additional 66,983 shares during the period. Finally, Private Wealth Partners LLC boosted its holdings in Amgen by 30.0% during the second quarter. Private Wealth Partners LLC now owns 1,299 shares of the medical research company's stock worth $406,000 after buying an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on AMGN. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Piper Sandler lowered their target price on Amgen from $344.00 to $310.00 and set an "overweight" rating on the stock in a report on Thursday, January 2nd. Deutsche Bank Aktiengesellschaft cut their price target on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Robert W. Baird restated an "underperform" rating and set a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $314.91.

Amgen Trading Down 0.7 %

Shares of Amgen stock traded down $1.98 during trading hours on Friday, reaching $262.23. The stock had a trading volume of 2,721,781 shares, compared to its average volume of 3,053,942. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm has a market capitalization of $140.96 billion, a price-to-earnings ratio of 33.58, a P/E/G ratio of 2.91 and a beta of 0.56. The firm has a 50 day simple moving average of $279.10 and a two-hundred day simple moving average of $308.76.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts' consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion for the quarter, compared to analysts' expectations of $8.50 billion. During the same period in the previous year, the company posted $4.96 earnings per share. Amgen's revenue was up 23.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This is an increase from Amgen's previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.63%. Amgen's dividend payout ratio is presently 121.90%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.